| 產(chǎn)品編號 | bs-1599R-BF350 |
| 英文名稱 | Rabbit Anti-Calpain 2/BF350 Conjugated antibody |
| 中文名稱 | BF350標記的鈣激活的中性蛋白酶2抗體 |
| 別 名 | Calcium activated neutral proteinase 2; Calcium activated neutral proteinase; CALP80; Calpain 2 (m/II) large subunit; Calpain 2 catalytic subunit; Calpain 2 large catalytic subunit; Calpain 2 large subunit; Calpain large polypeptide L2; Calpain M type; Calcium-activated neutral proteinase 2; CALP80; Calpain 2, large [catalytic] subunit; Calpain M-type; Calpain-2 catalytic subunit; Calpain-2 large subunit; CAN2_MOUSE; M-calpain; Millimolar-calpain; Calpain2; CANP 2; CANP L2; CANP2; CANPL 2; CANPL2; CANPml; Capa2; CAPN 2; CAPN2; FLJ39928; M calpain; M calpin; M type; mCANP; Millimolar calpain. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 細胞生物 信號轉(zhuǎn)導(dǎo) 新陳代謝 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, Mouse, (predicted: Rat, Dog, Cow, Sheep, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 78kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from mouse Calpain 2 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Calpain, and m calpain, also known as Calpain 2, are intracellular, calcium dependent cysteine proteases. Mu calpain has a micromolar sensitivity (thus the mu) as compared to the millimolar calcium sensitivity of m calpain. Both Calpains 1 and 2 are composed of an 80 kD subunit and a 30 kD subunit. Whereas the 30 kDa subunit is shared by both enzymes, the larger catalytic subunits are different and exhibit the distinct Ca++ requirements that are suggested by their names. The calpains have papain like activity, thus the pain nomenclature. Both Calpain 1 and Calpain 2 are ubiquitously expressed, and are countered by the endogenous calpain inhibitor, calpastatin. Other calpain family members (calpain 94, ncl2, ncl3, etc) have more limited tissue distribution, and perhaps different functions. The calpain family members consist of a common small subunit (Calpain 4), and a large variable subunit. It is not clear that all calpains contain a small subunit. Domains in the large subunit include the amino terminal domain I, the proteinase domain II, domain III, and the EF hand domain IV. The calpains appear to serve multiple physiological roles, and ideas concerning the functions of these enzymes are in a state of rapid flux. Function: Calcium-regulated non-lysosomal thiol-protease which catalyze limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction. Subunit: Forms a heterodimer with a small (regulatory) subunit (CAPNS1). Subcellular Location: Cytoplasm. Cell membrane. Note=Translocates to the plasma membrane upon Ca(2+) binding. Tissue Specificity: Ubiquitous. Similarity: Belongs to the peptidase C2 family. Contains 1 calpain catalytic domain. Contains 2 EF-hand domains. Database links: Entrez Gene: 824 Human Entrez Gene: 12334 Mouse Omim: 114230 Human SwissProt: P17655 Human SwissProt: O08529 Mouse Unigene: 350899 Human Unigene: 19306 Mouse Unigene: 6822 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 鈣蛋白酶2(calpain2)也是一族鈣離子依賴性的、水解半胱氨酸的蛋白酶,廣泛存在于全身各臟器組織中。鈣蛋白酶參與不同細胞過程,包括細胞骨架和細胞膜附著的構(gòu)型重建、不同的信號轉(zhuǎn)導(dǎo)途徑和細胞凋亡等. |
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
